Glutamate Ionotropic Receptor Kainate Type Subunit 3 (GRIK3) is an important excitatory neurotransmitter receptor that plays a significant role in various neurodegenerative diseases. However, the biological functions of GRIK3 in malignancies are largely unknown because of limited related studies. Here, we primarily reported that the expression of GRIK3 was higher in breast cancer tissues than in adjacent noncancerous tissues. 
| INTRODUCTION
Breast cancer is one of the most serious threats to the health of women and is the leading disease in gynecological oncology. However, current conventional therapeutic targets for breast cancer treatment are still limited and drug resistance has become a growing problem. Therefore, developing novel therapeutic targets and designing targeted drugs will greatly improve the clinical treatment of breast cancer.
Ionotropic glutamate receptors (iGluRs) serve as the first messenger of glutamic acid through binding to glutamic acid and mediating the signal transmission. iGluRs are divided into three subfamilies on the basis of the structural similarity: N-methyl-d-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-iso-xazolepropionic acid and kainate receptors (KA-R). 1 Glutamate receptor ionotropic, kainate 3 (GRIK3) is the member of the ionotropic glutamate KA-R subfamily, a branch of glutamate receptor family, which plays a critical role in synaptic potentiation-an essential process for learning and memory. [2] [3] [4] [5] [6] To our knowledge, few studies have reported on the association of GRIK3 with cancer. The expression of GRIK3 was found in rhabdosarcoma, neuroblastoma, thyroid tumor, lung cancer, breast cancer, astrocytoma, multiple myeloma, glioma, and colorectal cancer. 7 Moreover, the GRIK3 gene was found to be methylated across all stages of lung adenocarcinoma, indicating that GRIK3 might be an epigenetic marker for diagnosis. 8 Recently, Gong et al 9 showed that GRIK3 expression could serve as an independent prognostic biomarker and a novel treatment target for patients with gastric cancer. However, the precise mechanism by which GRIK3 expression influences cancer progression remains unclear.
It has been shown that GRIK3 is enriched in the neuroactive ligand receptor interaction pathway and haploinsufficiency of GRIK3 may be responsible for the severe developmental delay. 2, 9, 10 Interestingly, a previous study indicated that, in breast cancer, multiple estradiol (E2) stimulated or inhibited genes also enriched in the neuroactive ligand receptor interaction pathway were able to affect the cell proliferation. 11 On the basis of the current studies, we proposed that GRIK3 might function in the development of breast cancer.
In the present study, we sought to gain new insights into the role of GRIK3 in the progression and development of breast cancer. Our study aimed to reveal the expression and clinical significance of GRIK3 in breast cancer, explore further whether the overexpression of GRIK3 protein is a key step in the growth and metastasis of breast cancer, and explore the specific molecular mechanism GRIK3 affects breast cancer development. 
| MATERIALS AND METHODS

| Cell lines and culture condition
| Statistical analysis
The data were presented as mean ± standard error of the mean. All experimental data were analyzed using the SPSS 13.0 (SPSS Inc, Chicago, IL) and Graphpad Prism 6 software. Kaplan-Meier plots and the log-rank test were used to construct the survival curve. Paired or independent the Student t test was used to compare two groups with Gaussian data. Differences were considered significant when the P value was less than 0.05. (*P < 0.05, **P < 0.01 and ***P < 0.001)
| Immunofluorescence assay
The cells were seeded on coverslips laid in six-well plates and cultured at 37°C in 5% CO 2 for 12 hours. Before staining, the cells 
| Mouse experiment
The design and conduct of all experiments using mice were 
| Transcription sequencing and differentially expressed gene analysis
Total RNA from assay or control cell sample was isolated using 
(A) stanford.edu/; Figure 1F ). Taken together, these results suggested that the mechanism underlying how GRIK3 was transcribed into mRNA and further translated into protein is complicated and requires further study, however GRIK3 expression at protein level could be served as a biomarker for breast cancer.
| GRIK3 promotes breast cancer cell proliferation and migration
Given the high expression level of GRIK3 in breast cancer tissues, we hypothesized that GRIK3 could be an oncogene. Heterogenous expression and knockdown of GRIK3 was generated in MCF-7 and MDA-MB-231, respectively (Figure 2A ). CCK-8 assay showed that overexpression of GRIK3 could promote the proliferation abilities of Figure 3D ). However, there were no significant differences in the weight between the two groups ( Figure 3C ). On the basis of these results, we concluded that GRIK3 is involved in the tumorigenesis of breast cancer. | 1319 the qPCR assay. Therefore, we focused on the direction of the following mechanism study on the SPDEF/CDH1 pathway.
3.5 | SPDEF and CDH1 mediated the cell proliferation, cell migration, and invasion abilities enhanced by GRIK3
CDH1 and SPDEF are closely associated with cancer cell metastasis.
To address whether the cell proliferation and migration abilities enhanced by GRIK3 depended on the downregulation of SPDEF/ CDH1, CDH1 and SPDEF were transiently expressed in GRIK3 stably expressing cell lines, MDA-MB-231 and MCF-7, respectively ( Figure 5A ). The ability of GRIK3-induced cell proliferation was significantly suppressed by the restoration of CDH1 or SPDEF expression ( Figure 5B) . Moreover, the enhanced migration and invasion activities by GRIK3 were also decreased upon the restoration of CDH1 or SPDEF expression in both MDA-MB-231
and MCF-7 cells ( Figure 5C-F) . Taken together, these results indicate that SPDEF/CDH1 signaling is required for the GRIK3-mediated cell proliferation, migration, and invasion of breast cancer cells.
| GRIK3 overexpression induced epithelial-mesenchymal transition
As the SPDEF/CDH1 pathway is involved in mechanisms regulating cellcell adhesions, mobility, and proliferation of epithelial cells and suppressed breast cancer metastasis through epithelial-mesenchymal transition (EMT), we hypothesized that GRIK3 might play an important role in EMT. Phase-contrast microscopy showed that the GRIK3-overexpressing cells lost cell-cell contacts and had spindle-shaped morphology, which are hallmarks of cellular morphologic changes during EMT ( Figure 6A ). Immunoblot assays demonstrated that E-cadherin, the epithelial markers, were inhibited, whereas mesenchymal markers, such as Vimentin, Slug, and N-cadherin were upregulated in GRIK3-overexpressing cells ( Figure 6B ). In contrast, knockdown of GRIK3 reduced the expression of Vimentin, Slug, and N-cadherin and increased Ecadherin expression ( Figure 6B) . Interestingly, the same tendency of protein expression changes of E-cadherin, Vimentin, Slug, and N-cadherin accorded with their mRNA expression changes, according to the RNA-seq data of GRIK3 overexpressing cells and control cells. Using immunofluorescence to visualize intracellular β-catenin, we observed an increase in β-catenin levels and the translocation of β-catenin from cell membrane to nucleus ( Figure 6C ). To validate whether the translocation of β-catenin is the key step for its transcriptional activation, we examined several downstream target genes of β-catenin. As shown in Figure 6D , the mRNA levels of c-myc, cyclin D1, MMP3, and MMP7 were upregulated in response to GRIK3 overexpression. Furthermore, overexpression of GRIK3 significantly enhanced the luciferase activity driven by β-catenin promoter, whereas the rescue assay showed that knockdown of GRIK3
by siRNA in GRIK3 overexpressing cells decreased β-catenin promoter activity. These results indicated that the expression of GRIK3 could promote EMT initiation and progression partly by β-catenin activation. 
| DISCUSSION
Mounting research has shown that many subtypes of the glutamate receptor family are important in the central nervous system and neurologic tumors. [12] [13] [14] However, whether this group of proteins have significant effects in malignancies remains to be discovered. As a member of the KA-R subfamily, our understanding of GRIK3 has hitherto been limited in its expression in different malignancies. Whether GRIK3 could switch some tumor phenotypes, such as cell proliferation, apoptosis, and metastasis, remains unclear. GRIK1, in the same family as GRIK3, is a novel susceptibility gene for HBV-related HCC, and was revealed by a large three-stage genome-wide association study. 15 GRIK2 is a tumor suppressor in gastric cancer. DNA hypermethylation of the GRIK2 promoter inhibited its expression and decreased cell migration capabilities. 16 These studies indicated that members of KA-R family play different roles in different malignancies. In this study, we provided evidence that the expression of GRIK3 is upregulated in breast cancer.
GRIK3 promotes cell proliferation and migration in vitro and tumor growth in vivo. Mechanically, GRIK3 could facilitate EMT through inhibiting the epithelial marker, CDH1, and its transcription factor SPDEF, while increasing the expression of the mesenchymal marker, such as ZEB1 and β-catenin.
SAM pointed domain containing ETS transcription factor (SPDEF), also known as prostate-derived ETS factor, belongs to the ETS (E26 transformation specific) transcription factor family and is a specific transcription factor which preferentially binds a GGAT DNA motif rather than the GGAA ETS family consensus sequence. The expression of SPDEF could be detected in multiple organs, including the airway, breast, gastric, prostate, and small and large intestinal epithelia, and is able to inhibit the cell proliferation. 17 It has also been demonstrated cell polarity and integrity. 21 In tumors, it functions as a powerful molecular barrier that inhibits cancer cell proliferation, shedding, invasion, and metastasis. 21 The absence of functional E-cadherin possibly caused by truncating mutations, loss of heterozygosity, and transcriptional repression is causal for invasive lobular breast carcinoma, which is a subtype of breast cancer. 22 In addition, it has
shown that E-cadherin improves IGF1R recruitment to adherens junctions, possibly resulting in receptor sequestration and signaling repression. The loss of functional E-cadherin would impair the adherens junction formation, and release IGF1R to re-localize to the entirety of the cell membrane where the IGF1 ligand is easily bound for initiating cancer signaling. Firfly-luc/Renilla-luc F I G U R E 6 Overexpression of GRIK3 promoted EMT. A, Phase-contrast microscopic images of GRIK3 overexpressing cells and the control cells. B, Western blot showing the effect of GRIK3 overexpression and knockdown on the expression of epithelial and mesenchymal markers in GRIK3 overexpressing cells and the control cells. This assay was repeated in triplicate. C, The expression of β-catenin levels between GRIK3 overexpressing cells and the control cells was observed under a confocal microscope. **P < 0.01 D, qPCR assay measuring the mRNA expression of β-catenin downstream target gene in response to GRIK3 overexpression. *P < 0.05, **P < 0.01, and ***P < 0.001. E, Relative luciferase activity promoted by β-catenin promoter was measured in control cells, GRIK3 overexpressing cells and GRIK3 overexpressing cells that transfected with siGRIK3. Luc: luciferase. *P < 0.05 by one-way ANOVA. ANOVA, analysis of variance; EMT, epithelial-mesenchymal transition; GRIK3, glutamate receptor ionotropic, kainate 3; mRNA, messenger RNA [Color figure can be viewed at wileyonlinelibrary.com] The present study is the first study suggesting that GRIK3 is an oncogene in breast cancer and is involved in the EMT pathway.
Although the biological functions of GRIK3 in breast cancer have been exposed only slightly, additional research should be conducted into the mechanics of its oncogenic effects, such as how GRIK3 inhibits the expression of CDH1 and is the structure of the GRIK3-centric protein interaction network. A greater understanding of membrane protein GRIK3 offers new opportunities for the design of anti-GRIK3 therapeutic strategies.
